Biostate AI is a biotechnology company revolutionizing healthcare through next-generation RNA sequencing and artificial intelligence. They have developed proprietary RNA sequencing technologies that drastically reduce costs by 50-70%, enabling large-scale data collection essential for AI-driven personalized medicine. Their integrated platform includes RNA sequencing services, AI-powered bioinformatics tools like OmicsWeb, Copilot, and QuantaQuill, which democratize complex data analysis for researchers without specialized expertise. Biostate AI aims to build the world's largest RNA sequencing database to train foundation AI models that predict disease outcomes and treatment responses, ultimately enabling personalized therapeutics. The company serves academic labs, pharmaceutical R&D, biobanks, clinical oncology research, and biotech startups, positioning itself as a leader in affordable, AI-enhanced molecular diagnostics with a global presence and strategic partnerships with top medical institutions.
Biostate AI is a biotechnology company revolutionizing healthcare through next-generation RNA sequencing and artificial intelligence. They have developed proprietary RNA sequencing technologies that drastically reduce costs by 50-70%, enabling large-scale data collection essential for AI-driven personalized medicine. Their integrated platform includes RNA sequencing services, AI-powered bioinformatics tools like OmicsWeb, Copilot, and QuantaQuill, which democratize complex data analysis for researchers without specialized expertise. Biostate AI aims to build the world's largest RNA sequencing database to train foundation AI models that predict disease outcomes and treatment responses, ultimately enabling personalized therapeutics. The company serves academic labs, pharmaceutical R&D, biobanks, clinical oncology research, and biotech startups, positioning itself as a leader in affordable, AI-enhanced molecular diagnostics with a global presence and strategic partnerships with top medical institutions.
Core offering: Low-cost RNA sequencing wetlab + AI bioinformatics platform
Total funding: $16M
Notable lead investor: Accel (Series A, 2025)
Company Overview
Problem Domain
Affordable, scalable multi-omics data generation and AI-driven interpretation for disease prediction, drug discovery, and clinical decision support.
Founded
2023
Industry
Biotechnology Research
Funding Track Record
Seed- 2024-07-08
Series A- 2025-05-20
$12M
Series A announced May 20–21, 2025
Investor Signal
“Backed by institutional and high-profile individual investors including Accel, Caltech, Gaingels, Matter Venture Partners and individual backers such as Dario Amodei and Emily Leproust.”
Founders
What we do
Related Companies
Company
HQ
Industry
Total Funding
Rejuve.AI
🇦🇪Dubai, AE
BiotechnologyDeepTech
-
Allozymes
🇸🇬Singapore, SG
BiotechnologyDeepTech
$20M
Starkin Solutions
🇮🇳Hyderābād, IN
DeepTechInformation TechnologySoftware
-
dimenso.ai
🇺🇸Boston, US
DeepTechSoftware
-
NeuroDiscovery AI
🇺🇸Alpharetta, US
BiotechnologyDeepTechHealth
-
Join the Team
Frontend Engineer
RemoteUS
Remote • US
Biostate. AI -
Frontend Engineer
Location:
Remote or Onsite (Bengaluru, India)
Job Type:
Full-time
Experience Level:
Mid-Senior
About The RoleKey Responsibilities
Teeming tracks opportunities at over 24,000 AI startups, then works with you to find (and land) the one you'll love.
Data Scientist
Full-timeNiš, RS
Full-time • Niš, RS
Product Designer
Part-timeNiš, RS
Part-time • Niš, RS
Data Scientist
Full-timeBelgrade, RS
Full-time • Belgrade, RS
Backend Developer
ContractHaifa
Contract • Haifa
DevOps Engineer
Part-timeSan Francisco, US
Part-time • San Francisco, US
Product Designer
Full-timeUtrecht, NL
Full-time • Utrecht, NL
Build and maintain front-end applications using React, Angular, and Next.js.
Implement responsive, user-friendly interfaces with minimal design hand-holding.
Translate product requirements and user needs into interactive features.
Write clean, reusable, and scalable code following best practices.
Optimize performance and ensure cross-browser compatibility and mobile responsiveness.
Work collaboratively with product managers, engineers, and occasionally designers. Stay current with modern front-end development trends and tools.
Required Qualifications
3+ years of front-end development experience in production environments.
Proficient in JavaScript (ES6+), TypeScript, HTML5, and CSS3/SASS.
Experienced in frontend development with expertise in routing, dependency injection (DI), component-based architecture, state management, form handling, and module-based application design.
Strong working knowledge of:
React.js, including hooks and component patterns.
Angular (v10+), especially its modular and service-oriented architecture.
Next.js, including server-side rendering and static site generation.
Demonstrated ability to design and implement interfaces independently with attention to usability and visual polish.
Familiarity with RESTful and/or GraphQL APIs.
Strong debugging and troubleshooting skills.
Preferred Qualifications
Knowledge of accessibility standards (WCAG) and front-end security practices.
Background in startup environments or product-first teams.
About Biostate AI, Inc.
Biostate AI is building generative models for predicting the evolution of living organisms' health following drug dosing, emphasizing safety and toxicity. By innovating new methodologies for collecting RNAseq and DNA methylation data at a fraction of the traditional cost, Biostate has curated a vast, proprietary, multi-species, multi-drug, multi-omics dataset. The company stands out for its patented tokenization and Universal Gene Embedding methods for transfer learning, enabling its generative AI models to forecast human and animal health states with unprecedented 1-day temporal resolution. Biostate AI is co-founded by David Zhang (former tenured professor at Rice University, former founder/CEO of NuProbe) and Ashwin Gopinath (former MIT professor, former founder/CTO of Palamedrix). Our individual investors include Dario Amodei (CEO of Anthropic), Joris Poort (CEO of Rescale), Michael Schnall-Levin (CTO of 10X Genomics), and Emily Leproust (CEO of Twist Biosciences), all leaders in fields relevant to our work. Institutional investors in Biostate include Accel Ventures, Matter Venture Partners, Vision Plus Capital, and Caltech Fund.
Our Culture
At Biostate AI, our core values are Honesty, Discipline, Efficiency, Initiative, and Meritocracy. Team members are encouraged and expected to take ownership of their projects, evaluate and decide effort allocation among multiple projects, continuously learn in an inter-disciplinary manner, provide direct feedback to management, continually challenge conventional assumptions and innovate from first principles, and contribute to the company's growth and success. We embrace a “move fast and break things” attitude, encouraging our team members to take calculated risks, experiment with new ideas, and learn from failures. We value the ability to move quickly, iterate on ideas, and push boundaries.
Join Biostate.ai in our mission to revolutionize the interface of artificial intelligence and biological research.
